tbuckley/cabot-search huggingface dataset:
Abstract 16365: Juvenile Skeletal Myoblast Has Greater Therapeutic Potentials in Regenerative Therapy Than Adult Sheet for Treating Chronic Myocardial Infarction in Juvenile Pig
Authors: Hideto Ozawa, Shigeru Miyagawa, Satsuki Fukushima, Yasuhiro Shudo, Akima Harada, Emiko Ito, Atsuhiro Saito, Takayoshi Ueno, Koichi Toda, Toru Kuratani, Yoshiki Sawa
Journal: Circulation (2013)

Background:  Autologous cell transplantation therapy has been shown to be effective in treating chronic myocardial infarction (MI). Meanwhile, the fundamental behaviors of juvenile-derived cells, including proliferation and sirtuin (Sirt) 1 expression, are different from those of adult-derived cells. We hypothesized that the therapeutic effects of autologous skeletal myoblast (SMB) sheet transplantation for treating chronic MI are different between juvenile and adult individuals.   Methods and Results:  Primary SMB cultures were established in male juvenile (2-month-old) and adult (10-month-old) mini-pigs. The ratio of Ki67-positive cells was significantly greater in juvenile cells than in adult cells (8 ± 3% vs. 3 ± 2%, P = 0.005). Sirt1, HGF, and SDF-1 mRNAs were significantly upregulated in juvenile cells than in adult, as assessed by real-time PCR (4.7 ± 3.3 vs. 1.4 ± 0.6, 4.0 ± 2.3 vs. 1.0 ± 0.4, and 1.6 ± 0.1 vs. 0.5 ± 0.4, respectively). Moreover, the culture medium contained a greater level of vascular endothelial growth factor in juvenile cells than in adult cells, as assessed by ELISA (1.2 ± 0.9 vs. 0.2 ± 0.2 μg/mL). Next, we induced chronic MI by the catheterized left anterior descending artery occlusion and revascularization method. Two months later, cultured SMBs were prepared as cell sheets and transplanted into corresponding MI-pigs (n = 4 each). Echocardiographically, the ejection fraction was significantly improved in both juvenile (27± 6% vs. 43 ± 4%) and adult (30± 1% vs. 45± 6%) pigs. In addition, the dissynchrony index was significantly improved in model juvenile pigs compared with sham-operated juvenile pigs (54 ± 4 vs. 149 ± 3 ms, respectively, P = 0.001), as assessed by 3-dimensional tracking echocardiography. Importantly, the number of CD31-positive capillaries in the infarct-border region was significantly and markedly greater in juvenile pigs than in adult pigs (8.7± 2.7% vs 3.3± 2.1%, p = 0.005).   Conclusions:  Skeletal myoblasts derived from juvenile pigs showed a greater proliferative and angiogenic potential than those derived from adult pigs, leading to enhanced positive therapeutic effects on chronic MI in juvenile pig. Autologous cell-sheet transplantation may be warranted as a novel treatment for pediatric cardiomyopathy.
Prognostic subgroups in childhood non-Hodgkin's lymphoma.
Authors: C R Pinkerton
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.8.1174 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2787841 Prognostic subgroups in childhood non-Hodgkin's lymphoma. C R PinkertonxC R PinkertonSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.8.1174 First Page PDF © 1989 by American Society of Clinical Oncology
Liver metastasis of meningeal hemangiopericytoma: a study of 5 cases
Authors: Regina C. Lo, Arief A. Suriawinata, Brian P. Rubin
Journal: Clinical and Molecular Hepatology (2016)

Mesenchymal tumors in the liver, whether primary or metastatic, are rare. Meningeal hemangiopericytoma (HPC) is characteristically associated with delayed metastasis and the liver is one of the most common sites. Despite its consistent histological features, a pathological diagnosis of HPC in the liver is sometimes not straightforward due to its rarity and usually remote medical history of the primary meningeal tumor. In this report, the clinicopathological features of 5 cases of metastatic HPC to the liver were reviewed and described. Keywords: Hemangiopericytoma; Liver; Metastasis
Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study.
Authors: T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba, K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi, T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. Okusaka
Journal: Journal of Clinical Oncology (2011)

4007 Background: S-1, an oral fluoropyrimidine, is one of the key drugs for PC in Japan. Phase II studies of S-1 alone as well as those of GS have shown high efficacy against the tumor as the first-line treatment of metastatic PC. Methods: The GEST study was a randomized, prospective, open-label, 3-arm, phase III study. Chemotherapy-naive patients with unresectable advanced PC, an ECOG PS of 0-1, with adequate organ functions were randomly assigned to receive GEM (1000 mg/m2, iv, d1, 8 and 15, q4w), S-1 (80/100/120 mg/day based on BSA, po, d1-28, q6w) or GS (GEM 1000 mg/m2, iv, d1 and 8 plus S-1 60/80/100 mg/day based on BSA po, d1-14, q3w). The primary endpoint was overall survival (OS) to assess the non-inferiority of S-1 alone and the superiority of GS to GEM, with a 90% power and a 1-sided alpha value of 0.0125 for each multiplicity-adjusted comparison. Secondary endpoints were progression-free survival (PFS), response rate (RR), safety, and quality of life (EQ-5D). Results: A total of 834 patients were enrolled from July 2007 to October 2009. We conducted this analysis after confirming over 680 events as expected. Demographic factors were well balanced. S-1 was confirmed to be non-inferior to GEM with respect to OS. There was no significant difference in OS between GEM and GS, while PFS differed significantly between these arms. (4.1M/5.7M, p value<0.0001) RR was 13.3%, 21.0%, and 29.3% in GEM, S-1, and GS respectively. Grade 3/4 toxicities (%) in GEM/S-1/GS were neutropenia 41.0/8.8/62.2, thrombocytopenia 11.0/1.5/17.2, anorexia 7.3/11.4/9.4, diarrhea 1.1/5.5/4.5. EQ-5D QOL score in S-1 was similar to GEM (p value=0.67), and that in GS was significantly better than that in GEM (p value=0.003). Conclusions: Without compromising QOL, oral S-1 provided similar efficacy and tolerable toxicity to GEM as the first-line treatment for PC. Our results suggested that GS contribute better QOL than GEM. Further clinical investigation might be needed to ensure the efficacy of GS. n MST HR (97.5%CI) P value GEM 277 8.8 M - - S-1 280 9.7 M 0.957 (0.780-1.175) 0.0003 (noninferiority) GS 275 10.1 M 0.875 (0.711-1.077) 0.1496 (superiority)
Paclitaxel (P), pegylated liposomal doxorubicin (PLD) and trastuzumab as 1<sup>st</sup>-line chemotherapy (chemo) in HER2/neu-positive (+) metastatic breast cancer (MBC)
Authors: A. Karabelis, C. Kosmas, N. Mylonakis, G. Tsakonas, K. Evgenidi, E. Kallistratos, L. Sava, A. Nikolopoulou, A. Gassiamis, C. Valavanis
Journal: Journal of Clinical Oncology (2006)

10663 Background: Addition of trastuzumab (Herceptin, H) to successive neoadjuvant taxane+anthracycline-based chemo in patients (pts) with HER-2 (+) breast cancer significantly increases the pathological complete response (CR) rates. PLD has considerably less cardiotoxicity compared to parent drug. The aim of the study was to evaluate the activity and safety of combining H with PLD and P as 1 st -line chemo in HER-2 (+) MBC pts. Methods: Inclusion criteria were: histologically confirmed MBC or relapsed after adjuvant chemo, ≥1 measurable lesion, adequate organ function, ECOG-PS 0–1, left ventricular ejection fraction (LVEF) by MUGA ≥55% (reevaluated after cycles 3 and 6). HER-2 positivity was determined by IHC and confirmed with CISH. Chemo was administered as follows: H 6mg/kg (8mg/kg-1 st cycle) infused over 90min, PLD 35mg/m 2 over 1hr, and P 175mg/m 2 over 3hrs on day 1, with prophylactic G-CSF, recycled every 3 weeks. In responders, H was administered as consolidation (6mg/kg/3wks) until disease progression. Results: From 10/2003–10/2005, 19 female HER-2 positive MBC pts were enrolled. Median age: 68 (range, 42–78). Metastatic sites were: lung 6, liver 1, bone 3, lymph nodes 11, soft tissue 5 [median: 2 (range, 1–4)]. Pts received a median of 6 (range, 1–8) for a total of 102 cycles. PLD was started at 35 mg/m 2 , but in pts with grade 3 hand-foot syndrome (HFS) dose was reduced by 25% (6 pts), or the drug was omitted for 1 cycle (1 pt). 17 pts completed 3–6 cycles and were evaluable for response, all treated patients were evaluable for toxicity. Response rates (RR) were 71%; CR 41%, PR 30%, SD 29%, with no PD. Two pts rendered operable had pCR. Toxicities were: HFS; grade 4: 1, grade 3: 6 (overall 37%), grade 3–4 neutropenia: 4, grade 3 anemia: 1, grade 3–4 mucositis: 2, and grade 2 alopecia: 19. Neither significant LVEF decline, nor symptomatic cardiac event was observed. It is too early to provide data on response duration, TTP, and OS, and these will be available at the meeting. Conclusions: H+P+PLD as 1 st -line chemo in HER-2(+) MBC pts is a very active and well tolerated regimen with no significant morbidity/mortality. HFS was the most relevant toxicity. The study is ongoing. No significant financial relationships to disclose.
Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate
Authors: Kim Boesen, Peter C. Gøtzsche
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 14705: Utility of Late Gadolinium Enhancement to Predict Response to Cardiac Resynchronization Therapy: A Meta-analysis
Authors: Marissa Edmiston, Ajay Vallakati, Ashish Aneja
Journal: Circulation (2014)

Introduction: Late gadolinium enhancement on cardiac magnetic resonance imaging (LGE-CMR) has been shown to predict adverse cardiovascular outcomes, especially ventricular arrhythmic events. Hypothesis: A few studies, limited by small sample size, have examined the relationship between myocardial scar and cardiac resynchronization therapy (CRT) response. We performed a meta-analysis to determine whether scar identified on LGE predicts response to CRT in cardiomyopathy. Methods: We searched PubMed and Embase for clinical trials reporting CRT response based on scar determined by LGE -CMR. Primary outcome was defined as improvement in NYHA class or echocardiographic parameters (not limited to but including dP/dT, radial strain and reduction of LV end systolic volume). Random effects model was used to pool the data across the studies. Results: After screening 1876 articles, we identified 14 clinical trials that met inclusion criteria. A total of 984 patients were included in the analysis. There was no significant heterogeneity across the studies (I 2 =30%, p= 0.13). Presence of scar on LGE-CMR decreased CRT response by 39% (RR: 0.61 (95% CI 0.53 - 0.71; p&lt;0.001). Exclusion sensitivity analysis did not change the effect size. Pooled analysis of studies reporting only ischemic cardiomyopathy revealed that any myocardial scar reduced CRT response by 38% (RR: 0.62 (0.44 - 0.86; p=0.004). Conclusions: The presence of any myocardial scar detected by LGE predicts sub-optimal response to CRT in cardiomyopathy. This shows that identification of scar using LGE- CMR can be used as an important risk stratification tool for CRT response.
Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy
Authors: Martin S. Maron, Ethan J. Rowin, Iacopo Olivotto, Susan A. Casey, Anna Arretini, Benedetta Tomberli, Ross F. Garberich, Mark S. Link, Raymond H.M. Chan, John R. Lesser, Barry J. Maron
Journal: Journal of the American College of Cardiology (2016)
A new approach to identify methylated genes involved in anticancer drug sensitivity
Authors: Takashi Kobunai, Shin Sasaki, Akio Ooyama, Toshinori Oka, Toshiaki Watanabe, Hirokazu Nagawa
Journal: Cancer Research (2006)

37    Purpose:  Epigenetic alteration including DNA methylation play an important role in carcinogenesis through silencing several tumor suppressor genes, however, the relationship between DNA methylation and anticancer drug sensitivity has not been well- defined. In this study, we searched for candidate genes whose expressions are diminished via promoter methylation by the combined analysis of determining CpG island methylator phenotype (CIMP) and genome-wide gene expression analysis using GeneChip, and examined their correlation to anticancer drug sensitivity.  Material and Method:  Genomic DNAs extracted from 38 human tumor xenografts consisting of 8 colon, 7 gastric, 7 lung, 6 pancreatic and 4 prostate cancers, were treated with sodium bisulfite, then were subjected to SYBR-green methylation specific real-time PCR to determine the methylation status of CpG island located within the MINT1, MINT2, MINT3 clone and the p16 promoter. CIMP+ was arbitrarily defined as xenografts with the presence of methylation at two or more of these sites. Total RNA was isolated from each xenograft using RNeasy kit and was subjected to microarray analysis using the HG-Focus GeneChip, which contains 8800 well-substantiated human genes. The generation of biotinylated cRNA probe and array hybridization were carried out according to the standard Affymetrix protocol. Comparative analysis between expression profiles in the xenografts was carried out with GeneSpring software. Gene expression profiles were compared using unpaired t-tests (with Welch9s correction for unequal variances) and multiple testing corrections to identify genes that were differentially expressed between CIMP+ and CIMP+ xenografts. The anti-tumor activity of CDDP against 31 xenografts was evaluated by the tumor weight ratio of the drug-treated to the control (T/C)  in vivo , and the correlation to the methylation status was examined.  Results and Discussion:  Sixteen out of 38 xenografts were categorized as CIMP+ xenografts. Twenty-five genes including UCHL1, THBS1, BASP1, CLDN1, PTPN13 and RAB38 whose expressions were significantly down-regulated in CIMP+ xenografts were identified. All 6 genes listed above were confirmed to be methylated in CIMP+ xenografts using methylation specific PCR. Some of them were previously reported to be methylated in human cancers or cell lines. The xenografts possessing methylated UCHL1 were significantly resistant to CDDP. Our approach turns out to be useful to identify new (candidates for) epigenetic altered genes influencing anticancer drug sensitivity.
Essential light chain S195 phosphorylation is required for cardiac adaptation under physical stress
Authors: Lisa-Mareike Scheid, Matias Mosqueira, Selina Hein, Mandy Kossack, Lonny Juergensen, Marion Mueller, Benjamin Meder, Rainer H.A. Fink, Hugo A. Katus, David Hassel
Journal: Cardiovascular Research (2016)

Regulatory proteins of the sarcomere are pivotal for normal heart function and when affected by mutations are frequently causing cardiomyopathy. The exact function of these regulatory proteins and how mutations in these translate into distinct cardiomyopathy phenotypes remains poorly understood. Mutations in the essential myosin light chain (ELC) are linked to human cardiomyopathy characterized by a marked variability in disease phenotypes and high incidences of sudden death. Here we studied the role of the highly conserved S195 phosphorylation site of ELC using heterozygous adult zebrafish lazy susan (lazm647) in regulating contractile function in normal physiology and disease. Echocardiography revealed signs of systolic dysfunction in otherwise phenotypically unremarkable heterozygote mutants. However, after physical stress, heart function of laz heterozygous zebrafish severely deteriorated causing heart failure and sudden death. Mechanistically, we show that upon physical stress, ELCs become phosphorylated and lack of S195 dominant-negatively impairs ELC phosphorylation. In vitro motility analysis with native myosin from adult heterozygous hearts demonstrates that S195 loss, specifically following physical stress, results in altered acto-myosin sliding velocities and myosin binding cooperativity, causing reduced force generation and organ dysfunction. Using adult heterozygous zebrafish, we show that ELC S195 phosphorylation is pivotal for adaptation of cardiac function to augmented physical stress and we provide novel mechanistic insights into the pathogenesis of ELC-linked cardiomyopathy.
Response to Letters Regarding Article, “Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis”
Authors: Marianna Fontana, Silvia Pica, Patricia Reant, Amna Abdel-Gadir, Thomas A. Treibel, Sanjay M. Banypersad, Viviana Maestrini, William Barcella, Stefania Rosmini, Heerajnarain Bulluck, Rabya H. Sayed, Ketna Patel, Shameem Mamhood, Chiara Bucciarelli-Ducci, Carol J. Whelan, Anna S. Herrey, Helen J. Lachmann, Ashutosh D. Wechalekar, Charlotte H. Manisty, Eric B. Schelbert, Peter Kellman, Julian D. Gillmore, Philip N. Hawkins, James C. Moon
Journal: Circulation (2016)
Six months compared with 12 months of capecitabine as adjuvant chemotherapy for stage III (Dukes' C) colon cancer: Rationale for the open-label randomized phase III study, JFMC37-0801.
Authors: T. Takahashi, K. Yoshida, C. Hamada, J. Sakamoto, T. Satoh, S. Sadahiro, H. Mishima, M. Watanabe, K. Sugihara, N. Tomita
Journal: Journal of Clinical Oncology (2011)

517 Background: The standard duration of adjuvant chemotherapy (CT) in patient with stage III colorectal cancer is 6 months. On the other hand, no clinical trial which investigate an optimal duration of oral chemotherapeutic agents has yet been implemented for adjuvant treatments. According to the ACCENT database (Sargent, et al. J Clin Oncol 27: 872- 877, 2009), 83% of recurrences in stage II and III pts have occurred within the first 3 years after surgery and peak was observed around one year after surgery. Also, single-agent FU-based adjuvant CT reduced the hazard rate of OS, DFS, and TTR, although the peak of events around one year was still remained especially for stage III pts. We analyzed the data of recurrent risk of curatively resected colon cancer pts provided by JFMC7-1-7-2-15, X-ACT. Surgery alone group and 6 months CT (5FU/LV or capecitabine [Cape]) showed highest peak between 12 months to 18 months after surgery, but 12 months oral 5-FUs group did not show recurrence peak between 12 months to 18 months after surgery. Therefore, to clarify the benefit of 12 month administration of Cape, we planned a phase III randomized trial for a comparison of 6 months treatment and 12 months treatment. Methods: JFMC37 is a multicenter, randomized phase III trial. Patients with fully resected stage III colon or recto sigmoid cancer were eligible. Patients were randomized 1:1 to receive Cape of 6 months (arm A) or Cape of 12 months (arm B). Primary endpoint is disease-free survival. The statistical design is based on superiority hypothesis; 5-yrs DFS is 60% in arm A, 67% in arm B; unilateral α=0.05, 1-β=0.8; and planed accrual is 1200 pts. Results: Between September 2008 to December 2009, 1,304 pts were randomized. Patients characteristics are (armA/armB); number 653/651, gender M352-F301/M343-F308, median age 65 years/65 years, ECOG PS=0-1 620-33/632-19, involvement of lymph nodes=N0-N1-N2 503-130-20/499-128-24. There were no differences in baseline characteristics between arm A and arm B. Conclusions: This trial is expected to show if 1 year adjutant chemotherapy with capecitabine can reduce the peak of recurrence in 1 year and provide long-term OS benefit. [Table: see text]
Abstract 14598: The Novel Cardiac Biomarker Secretoneurin Provides Independent Prognostic Information in Severe Sepsis and Septic Shock: Data From the ALBIOS Study
Authors: Helge Røsjø, Serge Masson, Pietro Caironi, Mats Stridsberg, Caterina Fanizza, Geir Christensen, Gabriella Moise, Maria Cristina Urbano, Luciano Gattinoni, Roberto Latini, Torbjørn Omland
Journal: Circulation (2015)

Background: Plasma secretoneurin (SN) is directly correlated to cardiomyocyte Ca 2+ handling and provides independent prognostic information in cardiovascular disease. Whether SN may predict mortality in patients with severe sepsis or septic shock is not established. Methods: We measured SN levels in serial plasma samples collected on days 1, 2, and 7 in 958 patients enrolled in the multicenter, open-label, randomized, controlled ALBIOS trial, that tested either 20% albumin and crystalloid solutions or crystalloid solutions alone in patients with severe sepsis or septic shock. Endpoints were ICU or 90 day mortality. Results: SN levels on day 1 were higher in non-survivors compared to survivors, both for ICU mortality (235 [Q1-Q3 188-290] vs. 192 [155-246] pmol/L, p&lt;0.0001) and for 90 day mortality (227 [183-283] vs. 188 [154-234] pmol/L, p&lt;0.0001). Admission SN levels were influenced by age and lactate, creatinine and NT-proBNP levels. Stratifying patients according to SN quartiles on day 1 separated survivors and non-survivors during follow-up (Figure). After adjusting for clinical risk factors, SAPS II and SOFA scores, and cardiac biomarkers (hs-cTnT and NT-proBNP), SN levels (logarithmical transformed) on day 1 remained significantly associated with ICU mortality (OR 1.29 [95% CI 1.07-1.55], p=0.007) and 90 day mortality (OR 1.22 [1.02-1.47], p=0.03). SN levels on day 2, but not day 7, were also independently associated with ICU and 90 day mortality. SN levels on day 1 and 2 improved prognostic accuracy for ICU and 90 day mortality as assessed by the category-free net reclassification index. We found no interactions between SN levels and randomization to albumin replacement for prediction of mortality during follow-up. Changes in SN levels over time were not predictive of subsequent mortality. Conclusion: SN provides incremental information to established risk models and cardiovascular biomarkers in patients with severe sepsis and septic shock.
Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.
Authors: N Jaffe, R Robertson, A Ayala, S Wallace, V Chuang, T Anzai, A Cangir, Y M Wang, T Chen
Journal: Journal of Clinical Oncology (1985)

A randomized two-arm study was undertaken to determine relative tumoricidal effects of intra-arterial cis-diamminedichloroplatinum II (I/A-CDP) and high-dose methotrexate with citrovorum factor rescue (MTX-CF) in the treatment of the primary tumor in patients with osteosarcoma. Responses were evaluated by clinical, radiographic, angiographic, and pathologic parameters. Fifteen patients were randomized to receive MTX-CF and 15 to I/A-CDP. In the MTX-CF arm there were four responses (three complete responses, one partial response) whereas in the I/A CDP arm there were nine responses (seven complete responses, two partial responses). Two patients who failed MTX-CF and requested alternative treatment with I/A-CDP also responded. The total I/A-CDP response was 11/17.